Navigation Links
Stem Cell Sciences Enters into Services Agreement with Huntingdon's Disease Research Group, CHDI Foundation Inc.
Date:11/10/2008

CAMBRIDGE, England, November 10 /PRNewswire-FirstCall/ --

- ("Stem Cell Sciences", "SCS", "the Company")

Stem Cell Sciences plc (AIM:STEM, ASX:STC), a company focused on the commercialisation of stem cells and stem cell technologies, announces that it has entered into an agreement with CHDI Foundation, Inc., to support the standardisation of CHDI's novel mouse embryonic stem (ES) cell lines. CHDI is a US non-profit organisation pursuing treatments for Huntington's disease (HD). The cell lines have been produced over a period of several years under varying conditions, and conversion to a standard methodology is expected to facilitate their use in HD-related research towards the development of new HD drugs and diagnostics.

CHDI and its collaborators have developed a unique series of 20 ES cell lines from genetically modified mouse models that mimic aspects of Huntington's disease. These cell lines and mouse models represent an important tool for medical researchers to use in a wide variety of research programmes in HD, a genetic neurological disorder affecting 7 in 100,000 people. High-quality mouse ES cells are expected to be important and valuable for drug target validation and drug screening efforts.

Under the service agreement announced today, SCS will create standard culture conditions for CHDI's mouse ES cell lines using its serum-free and feeder-free ESGRO Complete(TM) media. Financial terms have not been disclosed. Initially, SCS will convert three cell lines to the standardised culture conditions and will monitor their viability and stability during this process. If successful, the Company may have the opportunity to apply its proprietary technologies across the entire range of CHDI's mouse ES cell lines, as well as providing the Foundation and researchers with media and reagents for future programmes.

"Switching these cell lines to ESGRO Complete(TM) media will allow researchers around the world to apply uniform media and growth conditions for easy maintenance of CHDI's mouse model ES cell lines, removing a substantial source of experimental variability," said George Murphy, Senior Vice President of SCS LLC. "The deal is a further validation of the quality of SCS' media, and repeat use of CHDI's cell lines is expected to generate further revenue growth from ESGRO Complete(TM)."

"The experience of Stem Cell Sciences in standardising conditions for growing stem cells should help accelerate the evaluation of the various mouse ES cells for HD target validation and drug discovery programs. Working with SCS furthers CHDI's goal of making high quality reagents available to the HD research community," said Dr Jamshid Arjomand, Director of Basic Research at CHDI, overseeing the Foundation's stem cell initiative.

ESGRO Complete(TM) and several other proprietary SCS media products are distributed worldwide under an exclusive licence agreement with Chemicon/Millipore Corporation.

About Stem Cell Sciences plc

Stem Cell Sciences (SCS) is an international research and development company focusing on the commercial application of stem cell biology technologies for drug discovery and regenerative medicine research. Stem Cell Sciences is now focussing on building revenues through the sale of products, collaborative research and licensing deals with international biotechnology and pharmaceutical companies.

Stem Cell Sciences has a substantial portfolio of patents and patent applications in both adult and embryonic stem cell fields. The Company has been active in the stem cell research field since 1994, principally focused on technologies to grow, differentiate, and purify adult and embryonic stem cells. These include technologies to permit the generation of highly purified stem cells and their differentiated progeny (specialised tissue cell types) for use in genetic, pharmacological and toxicological screens. Moreover, these technologies may be able to provide pure populations of appropriate cell types for transplantation therapies in the future.

The Company has its main research base and headquarters in Cambridge, UK with a second research base in Monash near Melbourne, Australia and a business development office in San Francisco, USA.

For further information on the company please visit: http://www.stemcellsciences.com.

About Huntington's Disease

Huntington's disease is a familial disease caused by a mutation in the huntingtin gene. Each child of a parent with a mutation in the huntingtin gene has a 50-50 chance of inheriting the mutation. As a result of carrying the mutation, an individual's brain cells fail and die leading to cognitive and physical impairments that, over the course of the disease, significantly impair the individual's quality of life and ultimately causes death. Symptoms of Huntington's disease, which generally develop in midlife and become progressively more debilitating as time passes, can also develop in infancy or old age. Once overt symptoms start, patients live for about 15 to 20 years. One person in 10,000 is believed to carry a mutation in the huntingtin gene. There is currently no way to delay the onset of symptoms or slow the progression of Huntington's disease.

About CHDI Foundation, Inc.

CHDI is a non-profit organization with a mission to rapidly discover and develop drugs that delay or slow Huntington's disease. CHDI supports an international network of research laboratories from academia and industry pursuing novel therapies for the treatment of Huntington's disease. As a collaborative enabler, CHDI seeks to bring the right partners together to identify and address critical scientific issues and move drug candidates to clinical evaluation as quickly as possible. More information about CHDI can be found at http://www.chdifoundation.org.

For further information, please contact:

Stem Cell Sciences plc (United Kingdom)

Alastair Riddell, CEO

Tim Allsopp, Chief Scientific Officer

+44(0)1223-499160

Stem Cell Sciences llc (USA)

George Murphy, Vice President Business Development

+1-415-495-7340

Stem Cell Sciences pty ltd (Australia)

Paul Bello, Operations Manager

+61(0)400-500-495

CHDI Foundation, Inc.

Bonnie Lee La Madeleine, Communications Director

Tel: +1-310-342-5524

Bonnielee.lamadeleine@chdifoundation.org

Citigate Dewe Rogerson (For SCS, United Kingdom)

Mark Swallow / Emma Palmer Foster / Amber Bielecka

+44(0)20-7638-9571

Talk Biotech (For SCS, Australia)

Fay Weston, Director

+61(0)422-206-036

Daniel Stewart & Company (NOMAD to SCS, United Kingdom)

Simon Leathers / Simon Starr

+44(0)207-776-6566


'/>"/>
SOURCE Stem Cell Sciences plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference
2. Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments
3. Advanced Life Sciences Announces Third Quarter 2008 Financial Results
4. LI-COR Biosciences and Mandel Scientific Company Inc. Announce Distribution Agreement
5. Vineland Welcomes Dr. Isabelle Lesschaeve as Research Chair, Sensory and Consumer Sciences
6. Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2008 Financial Results
7. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
8. Genomas to Present at Life Sciences & Healthcare Venture Summit
9. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Neurocrine Biosciences Reports Third Quarter 2008 Results
11. Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... , ... Global Stem Cells Group, a world ... Cells Network (GSCN) to distribute exosome injection and other biological products to stem ... Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El Salvador, Venezuela, Peru, Ecuador, Paraguay, Puerto ...
(Date:2/10/2016)... Md. , Feb. 10, 2016  The Maryland ... Busch , has announced that University of Maryland School ... PhD, MBA and University of Maryland Medical System President ... of the "Speaker,s Medallion," the highest honor given to ... of Delegates. Dean Reece and Mr. ...
(Date:2/10/2016)... -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company ... for the treatment of prostate, brain, lung, head and ... for the second quarter and six months of fiscal ... --> --> Revenue was $1.19 ... ended December 31, 2015, a 12% increase compared to ...
(Date:2/10/2016)... ... 2016 , ... HOLLOWAY AMERICA, a leading custom stainless steel ... Chapter 21st Annual Vendor Exhibition on Thursday, February 18, 2016. The Rocky Mountain ... annual event, which will run from 3:00 p.m. - 8:30 p.m. at The ...
Breaking Biology Technology:
(Date:2/8/2016)... Republic , February 8, 2016 ... global payment platform which presents innovation for clients, ... Authentication feature called VoiceKey. --> Worldcore ... which presents innovation for clients, comfort and unbeatable ... VoiceKey. --> Worldcore is ...
(Date:2/4/2016)... The field of Human Microbiome research ... popular hubs of the biotechnology industry. While the ... of human microbiota, have garnered a lot of ... space has literally exploded in terms of both ... focuses on biomedical aspects of research, development, and ...
(Date:2/3/2016)... 3, 2016 --> ... report "Automated Fingerprint Identification System Market by Component (Hardware ... (Banking & Finance, Government, Healthcare, and Transportation) and Geography ... market is expected to be worth USD 8.49 Billion ... 2015 and 2020. The transformation and technology evolution from ...
Breaking Biology News(10 mins):